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1. Introduction 
With improving technology and accumulation of knowledge, there has been a constant 
improvement in the understanding of various anomalies affecting the human population. 
Still, a lot is yet to be done. The prognosis of any aberration in the living system which 
may result in disease/syndromes/death is dependent on multiple variables. These 
include the overall parameters defining the health of an individual like age, nutrition and 
environment. Further, the family health scenario is suggestive of health status of an 
individual concerned. This is where the inherited factors constituting the genome are 
involved.
2. Differential gene expression and correlation with human 
diseases/syndromes
Alterations in the genome can be either inherited or acquired. These alterations may or may 
not lead to disease. Moreover, not all the acquired alterations are passed on to the next
generation. We need to address a few questions to be able to comprehend the situation.
What factors decide the fate of a gene as if to be expressed or not, how much and when?  
What alterations in genes lead to diseases? Which conditions are inherited? Are there ways
by which the body tries to repair these aberrations? And finally, can the affected part of the 
genome be replaced in a way that the individual becomes healthy again? 
The expression of a gene is a very tightly regulated process with reference to when, where 
and how much to be expressed.  A detailed discussion of the same is beyond the scope of 
this article. However, it’s worth mentioning that sequence and expression variations can 
sometimes be directly correlated to a diseased situation. The alterations in sequence may or 
may not be inheritable depending on whether the somatic or germline cells are getting
affected, respectively. There are situations where the somatic cells may be having an altered 
genome but the germline genome is protected from the same and hence the mutations are 
restricted to the present generation. This happens primarily because of two reasons. First, 
the germ cells are very much isolated as compared to the somatic cells and hence are often 
shielded from the causing agents in the environment or within. Secondly, the repair 
mechanisms active at the germline level are possibly much more efficient and sensitive than 
the ones at somatic level. Thereby, the chances of the alterations getting repaired before 
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316 Gene Therapy - Developments and Future Perspectives 
Disorder
Point
Mutation/s 
Aberration
in gene/s
Chromosomal
aberrations
Gene/s
involved
Chromosome Reference 
Cri du chat • 
Semaphorine 
F, Delta 
catenin,
hTERT
5 
Rodrifuez-
Caballero 
et al 2010
Fabry 
disease
• 
ǂ
galactosidase 
A 
X 
Saito et al 
2011 
Cystic
fibrosis 
• CFTR 7 
Madry et 
al 2011
Di George 
syndrome 
• TBX1 22 
Huh and 
Omitz 
2010 
De grouchy 
syndrome 
• 
MBP, 
Galanin 
receptor 
18 
Wilson et 
al 1979
Sickle cell 
anemia 
• 
Hemoglobin
gene 
11 
Mousa 
and Qari, 
2010 
Siderius X-
linked 
mental 
retardation 
syndrome 
• PHF8 X 
Abidi et al 
2007 
Wolf-
Hirschhorn 
syndrome 
• 
WHSC1, 
WHSC2 
4 
South et al 
2008 
Myotonic 
dystrophy
DM1 
• DMPK 19 
Magana 
and 
Cisneros
2010 
Myotonic 
dystrophy
DM2 
• ZNF9 3 
Raheem et 
al 2010
Huntingtons 
disease
 • HTT 4 
Warby et 
al 2011
CADASIL 
disease
• Notch3 19 
Valenti et
al 2011
Lesch-
Nyhan 
syndrome 
• HPRT X 
Gucev et 
al 2010
Crohns 
disease
• CARD15 16 
Raelson et
al 2007
Down 
syndrome 
• Trisomy 21 
Purvey et 
al 2010
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317Differential Gene Expression and Its Possible Therapeutic Implications 
Disorder
Point
Mutation/s 
Aberration
in gene/s
Chromosomal
aberrations
Gene/s
involved
Chromosome Reference 
Turner 
syndrome 
• 45, X
Lopes et al
2010 
Klinefelters
syndrome 
• 47, XXY
Judith et al
2009 
Table 1. Representative genetic disorders affecting human population along with the 
involved genes.
being packaged for the next generation are enhanced. Besides, not all genetic alterations lead
to diseases. There are some which make the individual susceptible to certain conditions 
while the actual occurrence and progression of the disease is dependent on environmental
factors and lifestyle. For instance, mutations in BRCA1 gene have been successfully used for 
epidemiological studies and predicting the risk of individuals to develop breast cancer. 
Precautions in lifestyle, drugs and environment thereon have helped in combating the
disease. Similarly, about 8 susceptibility loci are known for occurrence of prostate cancer 
and their detailed analysis is currently being pursued. So, what exactly are the possible
alterations in genes which may lead to diseases?
2.1 Involvement of genes in disease: mutations, deletions and translocations
Genetic alterations affecting the physiology of the individual, resulting in any disease or 
syndrome can be classified into three types. First of all, a point mutation 
(insertion/deletion) of a single gene results in the diseased phenotype.  Secondly, multiple
genes need to be affected for the diseased phenotype. Herein, the genes may be partly or
fully deleted, translocated or their length may increase or decrease due to change in copies 
of repeat elements. Lastly, the disorders caused by complete/partial loss or gain of
chromosome. Several examples of these anomalies along with their affected
genes/chromosomes are mentioned in table 1. The frequency of occurrence of these 
disorders varies across the world depending on the environmental factors, gene pool, 
lifestyle and even availability of health care facilities. The inheritance pattern of these 
diseases is dependent upon dominant or recessive nature of the causative gene as well as its
chromosomal localization. This has been discussed in detail in the next section.
2.2 Genes and diseases
2.2.1 Single gene disorders
The disorders caused by alterations in a single gene are called monogenic disorders. Over 
6000 such disorders are known till date and one in every 200 individuals is affected by them. 
Some of the common examples include cystic fibrosis, sickle cell anemia and Marfan 
syndrome. These follow the Mendelian laws of inheritance. The responsible gene may be
localized on autosome or sex chromosome. Further, the gene may be dominant or recessive 
in nature. Hence, the monogenic diseases can be classified as autosomal dominant,
autosomal recessive, sex linked dominant and sex linked recessive. Their inheritance 
patterns have been explained in figures 1-4. 
From the figures shown below, we can conclusively state that the inheritance pattern of a 
monogenic disorder is determined by three factors as follows 
a. The gene being dominant or recessive in expression
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318 Gene Therapy - Developments and Future Perspectives 
b. Localization of the gene on autosomes or sex chromosomes 
c. Status of the parents with reference to the causative gene. 
Fig. 1. The inheritance pattern of a monogenic autosomal dominant disorder. Here, the 
mother is diseased which leads to probability of an offspring getting affected to be ½ (50%).
However, it should be noted that the inheritance pattern in such cases would be
independent of the sex of the affected parent as well as that of offsprings getting affected.
This means even if father was diseased and mother normal, the same pattern would be
followed. The capital letter indicates affected allele while the small letter represents normal 
allele.  
Fig. 2. The inheritance pattern of a monogenic autosomal recessive disorder. In the present
example, both the parents are carriers for the gene which means they have one normal copy 
of the gene and one affected. In such a situation, the probability of the offsprings being
carrier for the disease is ½, being normal is ¼ and that of being diseased is ¼. Here also the 
sex of the parents or offsprings is irrelevant. The capital letter indicates affected allele while 
the small letter represents normal allele. 
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319Differential Gene Expression and Its Possible Therapeutic Implications 
Fig. 3. The inheritance pattern of a X linked dominant disorder. The affected allele has been 
shown in blue. Herein, sex of both the affected parent as well as offsprings is relevant. For 
instance, in the above example, where father is diseased and mother is normal, all the
daughters would be diseased while all the sons would be healthy.
Fig. 4. The inheritance pattern of a X linked recessive disorder. The affected allele has been 
shown in blue. Here again, sex of affected parent and offsprings are important. In case of a
diseased father and carrier mother, daughters have an equal chance of being diseased or 
carrier while the sons have an equal chance of being diseased or affected.
2.2.2 Multi-gene disorders 
The total genes present in any organism’s genome are often much less than the
characteristics or traits in the phenotype of that organism. This led to the understanding that
not every gene is responsible for an outcome in the phenotype. Thereon it has been 
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320 Gene Therapy - Developments and Future Perspectives 
established that many heritable traits such as eye colour, skin colour and height are
determined by multiple factors. Similarly, all diseases cannot be attributed to a single gene
defect. In most of the cases, more than one genetic element is involved, like in diabetes,
cancer and obesity. These disorders do not follow a simple inheritance pattern as monogenic
cases. Instead, the situation in the genome at multiple places needs to be monitored to
understand the inheritance. Such cases have lead to the defining of susceptibility loci 
wherein there are genomic targets whose monitoring have helped us to evaluate the risk of
an individual for getting the disease. Precautions at the lifestyle and genetic level (genetic
counselling) have proved very useful in controlling and monitoring the disease.
2.2.3 Mitochondrial genetic disorders  
Mitochondria are small circular or rod like organelles present in the eukaryotic cells 
cytoplasm and involved in the cellular respiration leading to the production of energy for 
the cell.  The mitochondrial genome follows “cytoplasmic inheritance” or “maternal
inheritance”. At the time of fertilization, the cytoplasm (having mitochondria) of the zygote
is contributed by ovum and hence the name.   This has been illustrated in figure 5. 
Fig. 5. Cytoplasmic inheritance of mitochondria. Formation of zygote (2n) requires the 
nucleic material from both the male and female gametes (1n each). However, the female
gamete is the sole contributor of cytoplasm and hence that of mitochondrial DNA. Thus, the 
inheritance of mitochondrial genome is cytoplasmic or maternal.
Each mitochondrion may have several circular pieces of DNA and each cell may have 
several mitochondria depending upon the activity of the cell. Even within the same cell, 
different mitochondria would be differing in their genetic material (heteroplasmy). These 
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321Differential Gene Expression and Its Possible Therapeutic Implications 
variations render uniqueness to every individual suffering from the same disease 
necessitating the need for personalized medicine. However, the most significant aspect of
mitochondrial genetics lies in its contribution to a range of disorders from cancer, diabetes, 
Parkinson’s disease, stroke to male infertility. Their exact involvement is still being 
explored. 
So far, we have seen the possible means by which different genes can contribute to diseases
either singly or in combination with others. Thereby, assessment of the expression level of
the genes becomes significant to ascertain their roles at the functional level. The various 
techniques employed for the same have been discussed in the next section. 
2.2.4 Y linked disorders
These are caused by alterations in genes located on the Y chromosome. The inheritance of Y
chromosome is restricted to males being passed on from father to son and so on. Since, the Y
chromosome doesn’t have a concerned homologous chromosome, so all genes would have a 
dominant inheritance pattern. This means all the sons of affected a father would be affected 
and as expected the daughters would be unaffected from the same. One such attribute is the
hypertrichosis pinnae or hair on the pinnae of ear. 
3. Techniques for analyzing gene expression
Realizing the importance of gene expression profiles under various situations, techniques
have been used for ascertaining the same. Northern blot has been one of the first approaches 
used for quantifying gene expression. Herein the RNA is blotted and hybridized before the
final quantification. However, two factors radically changed this approach. First was the
advent of polymerase chain reaction (PCR) and secondly, the discovery of reverse
transcriptase.
Polymerase chain reaction (PCR), discovered by Kary Mullis, is based on thermal thermal 
cycling where specific DNA stretch is targeted by DNA oligo-nucleotides (primers) and
amplification is carried out by thermo-stable Taq DNA polymerase. These steps result in 
manifold production of desired DNA sequence starting from relatively less template (Saiki
et al 1985, 1988; Mullis 1990). Since its discovery, it has become an indispensable tool in
genetics and molecular biology. It has been used successfully for a range of activities from 
clinical diagnostics, cloning, sequencing to carrying out site directed mutagenesis, besides 
others. 
Till the discovery of reverse transcriptase, the central dogma of molecular biology was as 
shown in figure 6
Fig. 6. The central dogma of molecular biology.
However, in 1970 Howard Temin and David Baltimore (Baltimore 1970; Temin 1964 a, b, c)
independently discovered the existence of an enzyme which could reverse transcribe RNA 
to DNA. The enzyme was named “reverse transcriptase” for its action and both the 
scientists shared the 1975 Nobel Prize for the discovery.  The central dogma was then 
modified as shown in figure 7.
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322 Gene Therapy - Developments and Future Perspectives 
Fig. 7. The central dogma of molecular biology with discovery of reverse transcriptase.
This discovery has had far reaching consequences in the understanding of many aspects of 
RNA viruses in particular (Hurwitz and Leis 1972; Kulesh et al 1987, Rodgers et al 1995).
Presently, we would be focussing on its significance in studying the expression of genes. 
Reverse transcriptase creates a single stranded DNA from RNA template. Thus, the RNA 
repertoire from a source can be reverse transcribed to cDNA wherein the relative levels of 
different genes would be a representation of their expression status. This has been discussed
in the subsequent sections. Also, this enzyme made it possible to access the eukaryotic 
coding sequences without the introns. Hence, it has been immensely helpful in 
understanding and analyzing the splicing of different genes. 
3.1 Reverse transcription
A combination of the above two approaches is being used exhaustively for the gene 
expression analysis. Herein, the total RNA is reverse transcribed to cDNA having repertoire 
of different transcribing genes in ratios comparable to their expression. These levels could 
then be estimated using labelled gene specific probes for hybridization and subsequently
comparing the signal intensities. However, with advancements in technology and
exhaustive information available about many genomes, more sensitive approaches are being 
used today. These include microarray and real time PCR which would be discussed in the
coming sections.   
3.2 Microarray analysis
The property of nucleotides to bind specifically (A-T; G-C) forms the essence of all
hybridization experiments. Small specific probes (oligonucleotide) have been made 
radioactive and employed for ascertaining the presence of genes using southern 
hybridization. The same principle and the need for screening for fate of thousands of targets
at the same time have driven the development of microarray technology. It began with the
analysis of 378 bacterial lysates having different sequences and as of now over 30000 genes
can be analyzed at one go. A flowchart for the microarray experiment has been shown in
figure 8. Microarray has been used successfully for a range of applications including gene 
expression profiling, comparative genomic hybridization, detection of SNPs and analysis of 
splicing (Hacia et al 1999; Lashkari et al 1997; Nuwaysir et al 2002; Pollack et al 1999; Schena
et al 1995; Shalon et al 1996) . A typical experiment for gene expression profiling involves 
hybridizing cDNA to an array of microscopic spots; each spot having a bound probe
(oligonucleotide specific for a gene) and finally detection of hybridization using different 
fluorescence or chemiluminescence.
3.2.1 Sample
A microarray experiment for profiling gene expression would require at least two sets of 
cDNA as the final detection of signal intensities need a reference point to assess their fate
(Wei et al 2004). For instance, the expression profile of genes in diseased individual would 
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323Differential Gene Expression and Its Possible Therapeutic Implications 
require a reference of a normal individual. Similarly, the profile in cells which have
undergone any treatment can be compared with respect to untreated cells. The two or more
sets of cDNA (of which one can be used as reference) hence constitutes the sample for 
microarray experiment.
The number of genes to be screened in an experiment varies. If no information is available 
regarding the targets to be screened, it’s advisable to go for exhaustive screening of all 
possible genes. However, if preliminary information is available as to which pathways
would be affected or which genes may be targeted in a particular situation; then,  it makes 
sense to have multiple probes for those set of genes rather than assessing the whole 
transcriptome. 
Fig. 8. Different steps in a microarray experiment.
3.2.2 Probes
The probes used in microarray experiment are short oligonucleotide sequences specific for a 
particular gene. In case some particular repertoire of genes needs to be focussed on, then 
multiple probes are designed on different regions of each gene to verify results.
3.2.3 Analysis
As mentioned earlier, the expression levels are indicated by post hybridization intensities, 
so an increase or decrease in intensities in relevance to the reference sample would give us
the expression profile of the studied genes. Since equal amounts of samples are used for 
hybridization, an increase in intensity would correspond to an increase in expression and 
vice versa. It has been explained by an illustration in figure 9. 
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324 Gene Therapy - Developments and Future Perspectives 
(A) 
(B) 
Fig. 9. The interpretation of microarray results. The above diagrammatic illustration 
represents microarray results. If (A) is taken to be the reference cDNA sample and (B) as that 
of the test sample then the final analysis shows comparative signal intensity of each spot.
Since each spot is attached to a probe for a specific gene, the variations in intensities of the 
same well from two sets would indicate the fate of that gene. For instance, the intensities in 
spots A12, C2, D1 and G12 have gone down considerably in (B) as compared to (A). This
reflects the reduction in corresponding genes expression. Contrastingly, positions A7 and 
H5 show an increase in the intensity in (B) as compared to (A) indicative of genes 
transcribing more in the situation. 
3.2.4 Advantages and limitations
Thus, the microarray analysis helps us have an idea about the fate of genes in different
circumstances. The greatest advantage of this approach lies in the ability to screen
thousands of targets in a single experiment. This becomes particularly significant if we are 
to study a disease or response to any chemical/stress/radiations wherein the genetic targets 
are not known.
However, the variations in intensities are reflective of expression profiles and these
intensities can be quantified as well but these quantifications are not the real representation 
of the relative expression of genes. This is primarily because the detection through 
fluorescence or chemiluminescence is an indirect approach. Though there have been 
improvements in detection but still a lot needs to be done (Tang et al 2007). Till date, 
microarray falls short in providing a numerical value with confidence as to how the
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325Differential Gene Expression and Its Possible Therapeutic Implications 
expression levels were affected. Moreover, the approach can be applied to only those 
organisms where exhaustive information is available about both the genome and its
corresponding transcriptome.   
3.3 Real time PCR
In conventional PCR methods, the product is visualized at the end of the reaction. Since, 
amplification of target sequence from template takes place in an exponential manner, at the
end of 20 amplification cycles the difference in intensities of products is not true 
representation of the difference at the beginning. This difference is all the more critical if we 
have to decide on the  gene expression levels from cDNA leading to diseased or affected  
phenotypes. Under such circumstances, the initial level of the target gene in cDNA needs to 
be determined. This has lead to the development of real time PCR wherein the actual PCR 
reaction can be monitored with the help of fluorescence dyes. Hence, the initial template can 
be quantified. It has been used successfully for estimating the relative expression of genes, 
copy number variations and allelic profiling besides others (Mackay et al 2002; Nailis et al 
2006; Nolan et al 2006; Spackman et al 2008). This article would focus on use of relative 
quantification (RQ) for ascertaining gene expression levels. 
Fig. 10. Different steps in real time PCR. The real time PCR reactions can be performed in
two ways: single step and two step. In single step approach all the 3 stages shown above 
take place in a single tube whereas in two step approach, stage 1 (cDNA preparation) takes 
place in one tube while the subsequent target specific PCR takes place in another tube.  
The relative expression studies require two things: cDNA preparation from RNA and PCR 
amplification using gene specific primers. An overview of the same has been provided in 
figure 10. There are two established approaches involved in real time reactions for detection
of PCR: SYBR green and Taqman.   
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326 Gene Therapy - Developments and Future Perspectives 
3.3.1 SYBR green assays
SYBR green (SG) is a dye which binds to any double stranded DNA. The DNA dye complex 
absorbs blue light (λmax=488nm) and emits green light (λmax=522nm), hence the name
(Zipper et al 2004). Its chemical structure has been shown in figure 11. 
Fig. 11. The chemical structure of SYBR green. Its IUPAC nomenclature is N',N'-dimethyl-N­
[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N­
propylpropane-1,3-diamine.
Fig. 12. A real time PCR assay using SG dye. As amount of DNA increases with every cycle 
more SG is bound to it corresponding to increase in fluorescence. 
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327Differential Gene Expression and Its Possible Therapeutic Implications 
An overview of real time PCR reaction using SG dye has been shown in figure 12. The SG 
dye has no binding specificity of its own and would bind to any dsDNA present. It even 
binds to ssDNA, though with a much lower affinity. Hence, while carrying out the reaction,
any additional DNA source would lead to false signal. To ensure that the signal we are 
observing as amplification is specific to the target from our template source we follow the
following steps 
a. Check for dissociation curve
b. Reaction controls 
Dissociation curve is the calculation of Tm of product after the reaction is over. A single
peak would be indicative of specific amplification while multiple peaks would refer to non 
specific detection. A reaction can be used for analysts only if the corresponding dissociation 
curve is having a single peak. Moreover, to check for any DNA/RNA contamination two 
controls are required. First, template where reverse transcription has not taken place and
secondly, no template control (NTC) wherein water is added as template. Any amplification 
in the first signifies impurity of RNA whereas in second it would refer to nucleic acid
contaminated water being used for reaction. Owing to the sensitivity of the reaction, all
these steps must be ensured for accurate results.
3.3.2 Taqman assays
The real time PCR assays employing taqman chemistries differ from those with SG
primarily in two aspects. First, in addition to the target specific primers employed for 
amplification, a probe is present located between the two primers. Secondly, the
fluorescence comes from labelled probe (5’ end) and hence is target specific unlike SG
binding to any DNA present. A representation of real time PCR using taqman chemistry is 
shown in figure 13. 
Fig. 13. A real time PCR assay employing taqman chemistry.
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328 Gene Therapy - Developments and Future Perspectives 
There are multiple options for labelling the probe like FAM and VIC. Since the probe is 
responsible for specificity, hence multiplex reactions can be carried out using taqman 
approach. This is not feasible when employing SG assays.  
3.3.3 Analysis
In order to understand the expression level of a target gene between 2 or more samples two
terms need to be introduced:  Endogenous control and Calibrator. Endogenous control is a 
gene whose expression level is known to be fairly constant. These include the various
housekeeping genes such as ǃ-actin, and GAPDH. The expression of control needs to be 
ascertained in all the samples. The calibrator is the sample in reference to which the
expression levels needs to be calculated for other samples. For example, if the purpose is
study the variations in expression level of androgen receptor (AR) in patients suffering from 
prostate cancer, then a normal person should be taken as calibrator. When a real time PCR
assay is performed it gives us the cycle in which the particular sample reaches threshold 
level. How this information is corroborated to give relative expression levels is explained 
below (Pfaffll 2001). 
If,  
X0 = number of target molecules at cycle number 0 
Xn = number of target molecules at cycle number “n” 
Ex = Efficiency of PCR amplification
Then, the equation for target amplification is as follows 
Xn = X0 x (1+Ex)n (1)
Similarly, for endogenous control, equation for amplification can be written as
 Rn = R0 x (1+ER)n (2)
The threshold cycle (Ct) is the cycle number at which the amplification crosses the threshold
fluorescence. This amplification would be constant for the target as well as endogenous
control. Hence the equations 1 and 2 can be written as 
XT = X0 x (1+Ex)Ctx (3) 
And 
RT = R0 x (1+ER)Ctr  (4)
Where, 
Ctx = threshold cycle number for target 
Ctr = threshold cycle number for endogenous control
Taking the ratios 
X0 x (1+Ex)Ctx / R0 x (1+ER)Ctr = K (constant) (5) 
Let’s assume both the amplifications are occurring with same efficiency. Thereby,  
Ex = Er = E (6)
Substituting 6 in 5 we get
 K= X0 x (1+E)Ctx / R0 x (1+E)Ctr  (7)
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329Differential Gene Expression and Its Possible Therapeutic Implications 
Normalizing the target with control the equation becomes
 K= XN x (1+E)ﾨCt  (8)
Where, 
X0 / R0 = XN (Normalized target) (9)
And 
ﾨCt = Ctx - Ctr (10) 
Rearranging equation 8, 
XN = K x (1+E)-ﾨCt (11)
Finally, comparing the value of XN for nay sample XNS with reference to the chosen calibrator 
XNC, relative quantification is given by 
Q = XNS / XNC = K x (1+E)-ﾨCtS / K x (1+E)-ﾨCtC = (1+E)-ﾨﾨCt (12)
Where, 
ﾨﾨCt = ﾨCtS - ﾨCtC (13) 
Considering the efficiency for both reactions to be 1, equation 12 for relative quantification 
becomes as follows 
RQ = 2-ﾨﾨCt (14)
Let’s take a hypothetical example to understand the same. Relative expression assays were 
done to ascertain the levels of AR expression in prostate cancer patients with reference to
normal males. Β-actin was taken as endogenous control. The CT values obtained and
subsequent calculations have been shown in table 2. From the table, it can be observed that
with reference to calibrator (expression level 1), the patients are showing up to 272 folds 
higher expression of AR. 
Similarly, expression profile can be obtained for n number of genes across different sample 
sets. Since the approach doesn’t quantify expression in absolute terms so it’s also known as 
relative quantification method. Further as the expression level is determined by value of
ﾨﾨCT the approach is often also referred to as ﾨﾨCT method. 
3.3.4 Advantages and limitations
The first and foremost advantage that real time has over other conventional methods is 
assigning a numerical value to expression levels with great accuracy. The assays are 
relatively easy to perform and design. However, there are few limitations as well. Though 
housekeeping genes have been used successfully as controls for long, several reports 
suggest that even their expression may be affected in certain cases. The way forward is to 
use multiple controls and select the one exhibiting least variations (Dhanasekaran et al 
2010). Further, designing assays wherein sufficient information is not available about the 
organism’s genome/transcriptome is very difficult. This is so because the specificity of the 
primers/probes cannot be ascertained conclusively. Moreover in case of genomes very rich 
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330 Gene Therapy - Developments and Future Perspectives 
Sample AR CT 
Avg. CT 
AR
ǃ-actin CT Avg. CT ǃ-actin
ﾨ CT 
(AR-ǃactin) 
ﾨﾨ CT 
(sampleﾨ CT ­
calibratorﾨ CT ) 
Relative 
expression 
(2-ﾨﾨCt ) 
Patient 1
24.34
24.39
8.45
8.47 15.92 -5.77 54.5624.45 8.43
24.39 8.53
Patient 2
26.89
26.91
9.76
9.77 17.17 -4.52 22.9427.01 9.88
26.85 9.67
Patient 3
22.12
22.15
8.55
8.55 13.6 -8.09 272.4822.09 8.48
22.24 8.61
Patient 4
28.67
28.59
8.98
8.92 19.67 -2.02 4.0628.49 8.88
28.60 8.91
Patient 5
24.52
24.38
9.98
10.03 14.35 -7.34 16224.39 10.08
24.24 10.1
Patient 6
25.31
25.25
9.58
9.55 15.7 -5.99 63.625.19 9.46
25.24 9.61
Normal 
(Calibrator) 
30.12
30.06
8.43
8.37 21.69 0 129.89 8.36
30.18 8.32
Table 2. An experimental result illustrating the calculation of relative expression using ﾨﾨ
CT method.
in GC content designing primers and probes with required taqman specifications has often 
proved difficult. Since each gene needs a specific assay to be designed, therein we can use
real time PCR only when we have candidate targets. It doesn’t give us exhaustive data 
indicative of potential targets; instead it helps us explore candidate targets once known 
through other approaches. All these limitations notwithstanding, real time PCR would 
continue is a very effective and accurate approach for studying gene expression. 
4. Targets for “Gene Therapy”
The identification of genetic basis of diseases would be significant only if we are able to use 
that information to be able to cure or at least manage the disease. There are many 
approaches that have been used for treatment and management of different diseases mostly
at the protein level. These include vaccination, antibiotics, hormones and a wide range of
drugs. Recently, the focus has been to “modify” or rather “correct” the gene alteration which 
caused the disease in its first place. This approach can be broadly described as what 
constitutes “gene therapy”. In principle gene therapy refers to the replacement of an affected
gene with a normal gene. This can be achieved primarily by two approaches:
a.  Ex-vivo: Cells are removed from the tissue where the affected gene needs to be 
expressing normally and a normal copy of the gene is introduced in these cells. 
www.intechopen.com
  
 
 
  
 
 
 
 
  
    
 
 
 
  
 
 
 
  
  
  
  
  
  
  
 
 
  
  
 
  
   
   
 
    
 
331Differential Gene Expression and Its Possible Therapeutic Implications 
Subsequently, these cells having a normal expression of the target gene are re­
introduced in the body.
b.  In-vivo: A normal copy of the gene is directly introduced in the body through viral
vectors or liposome mediated approach. 
There are various challenges which need to be considered while using gene therapy as a 
treatment option. Presently, we would focus on choosing a target for gene therapy rather
than the approach itself. 
a.  The first and foremost requirement for any gene to be targeted for gene therapy is that 
the defect in the gene should be responsible for the disease. When a gene is affected it 
may either stop expressing or express an altered non-functional protein. This protein
may need to be addressed. This situation is often referred to as dominant negative. In
such cases, besides introduction of a normal copy of the gene, the altered copy needs to
be removed as well. If  it cannot be removed there are two options, either silence the 
gene and introduce a normal copy or repair the gene itself. Both the approaches have
been used. 
b.  Secondly, it should be known that the introduction of a normal expressing gene in the
system successfully cures the diseased situation. This is relatively easy to determine in 
case of monogenic disorders. However, gene therapy can also be used in multi-factorial 
disorders. In such cases, it’s required to identify the gene which has a dominant
functional role. This should enable to control the multiple elements through one. 
c.  Thirdly, the expression profile of the target gene needs to be available. This would  
include the various tissues where the gene is expressed. If its differential expression in 
any particular tissue is leading to the disease that tissue needs to be targeted. 
d.  Fourthly, the feasibility of the target gene to be introduced to the concerned tissue
needs to be explored. The gene has to be present in the body such that it expresses only
in the desired tissues otherwise it may lead to complications.
e.  Lastly, the patient needs to be monitored for certain duration after successful
expression of the introduced gene. 
5. Conclusions
There has been a constant increase in our understanding of the genetic aspect of diseases, 
particularly in the last decade or so. This can be attributed to two reasons. First, the pace
of technology advancements has been the highest in this period. This has resulted in
faster, more sensitive and efficient generation as well as dispersal of data. Secondly, 
during this period there has been tremendous increase in public awareness and
participation in health programmes. This has made the analysis as well as predictions 
statistically significant. Moreover, awareness has lead to better diagnosis and 
management of diseases. Though situation has improved but globally there are still many 
areas where lots need to be done. Unless a disease and its pathogen are completely
eradicated from the world, the evolution of the pathogen may lead to more potent 
variants of the disease.   
The chances of an individual getting diseased while living in a safe suitable environment 
and having a balanced diet are very low. Primarily, it is our life style which is responsible
for our diseased body. Various socioeconomic and environmental factors are equally 
responsible for the life we live. However, awareness and precautions would be the best 
approach to stay healthy.
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The cause of diseases at the physiological level is the imbalance between the three pillars of
life; DNA, RNA and protein. Since DNA is the storehouse of all information, mostly, the
cause can be traced back to it. DNA is a sequence of nucleotides which governs life. There 
are several mechanisms which ensure that DNA remains uncorrupted. However if it does 
get affected there are means to get it repaired. These machineries act as barrier for any 
wrongful transmission of the genetic material across generations. Still, genetic diseases are 
inherited possibly contributing not only to the evolution of the species but also to that of the
disease.
Hypothetically, it should be possible to cure a disease which is caused by an alteration in 
gene by giving the body a normal copy of the gene. Even the body on its own tries to do the
same which often leads to gene duplications resulting in copy number variations. This 
thought has formed the basis of gene therapy. To achieve this in reality however, involves 
exhaustive information about the pathogenesis of the disease; genes involved; their 
sequence variations and expression profiles. Though the idea is very promising but for it to
be successful it needs to be used cautiously and in combination with other approaches. 
6. References
Abidi, F.E., Miano, M.G., Murray, J.C. & Schwartz, C.E. (2007) A novel mutation in the PHF8
gene is associated with X-linked mental retardation with cleft lip/cleft palate. 
Clinical  Genetics, Vol. 72, No. 1, pp. 19-22. 
Baltimore, D. (1970). Viral RNA dependent DNA polymerase in virions of RNA tumor 
viruses. Nature, Vol. 226, pp. 1209-1211 
Dhanasekaran, S., Mark Doherty, T., Kenneth, T., & TB Trials Study Group. (2010). 
Comparison of different standards for real-time PCR-based absolute quantification.
Immunology Methods, Vol. 354, No. 1-2, pp. 34–9.  
Gucev, Z., Koceva, S., Marinaki, A., Fairbanks, L., Kirovski, I. & Tasic, V. (2010) Lesch-
Nyhan syndrome: a novel complex mutation with severe phenotype.Clinical
Genetics Vol. 78, No. 3, pp. 296-7.
Hacia, J.G., Fan, J.B., Ryder, O., Jin, L., Edgemon, K., Ghandour, G., Mayer, R.A., Sun, B.,
Hsie, L., Robbins, C.M., Brody, L.C., Wang, D., Lander, E.S., Lipshutz, R., Fodor, 
S.P., & Collins, F.S. (1999). Determination of ancestral alleles for human single-
nucleotide polymorphisms using high-density oligonucleotide arrays. Nature 
Genetics, Vol. 22, pp. 164–167. 
Huh, S.H. & Ornitz, D.M. (2010). Beta-catenin deficiency causes DiGeorge syndrome-like
phenotypes through regulation of Tbx1. Development, Vol. 137, No. 7, pp. 1137-47. 
Hurwitz, J. & Leis, J.P. (1972). RNA-dependent DNA polymerase activity of RNA tumor viruses.
I. Directing influence of DNA in the reaction. J. Virology, Vol. 9, No. 1, pp. 116–29. 
Judith, L.R., Martha, P.D., Harvey, Kushner., Andrew, R.Z. &, and David P. R. (2009). An 
extra X or Y chromosome: contrasting the cognitive and motor phenotypes in
childhood in boys with 47,XYY syndrome or 47,XXY Klinefelter syndrome. Dev 
Disabil Res Rev. Vol. 15, No. 4, pp. 309–317. 
Kulesh, D.A., Clive, D.R., Zarlenga, D.S. & Greene, J.J. (1987). Identification of interferon-
modulated proliferation-related cDNA sequences. PNAS USA, Vol.  84, No. 23, pp. 
8453–8457.  
Lashkari, D.A., DeRisi, J.L., McCusker, J.H., Namath, A.F., Gentile, C., Hwang, S.Y., Brown,
P.O. & Davis, R.W. (1997). Yeast microarrays for genome wide parallel genetic and 
gene expression analysis. PNAS USA, Vol. 94, No. 24, pp. 13057–13062.  
www.intechopen.com
  
 
  
 
 
 
 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  
   
 
     
 
 
 
333Differential Gene Expression and Its Possible Therapeutic Implications 
Lopes, A.M., Burgoyne, P.S., Ojarikre, A., Bauer, J., Sargent, C.A., Amorim, A. & Affara,
N.A.(2010). Transcriptional changes in response to X chromosome dosage in the
mouse: implications for X inactivation and the molecular basis of Turner
Syndrome. BMC Genomics, Vol. 11, pp. 82.
Mackay, I.M., Arden, K.E. & Nitsche, A. (2002). Real-time PCR in virology. Nucleic Acids 
Research, Vol. 30, No. 6, pp. 1292–305.  
Mądry, E., Fidler, E., Sobczyńska-Tomaszewska, A., Lisowska, A., Krzyżanowska, P., 
Pogorzelski, A., Minarowski, L., Oralewska, B., Mojs, E., Sapiejka, E., Marciniak, R., 
Sands, D., Korzon-Burakowska, A., Kwiecień, J. & Walkowiak, J. (2011). Mild CFTR
mutations and genetic predisposition to lactase persistence in cystic fibrosis.
European J Human  Genetics, [Epub ahead of print]. 
Magaña, J.J. & Cisneros, B. (2010). Perspectives on gene therapy in myotonic dystrophy type
1.J Neurosci Res. [Epub ahead of print] 
Mousa, S.A.& Qari, M.H. (2010). Diagnosis and management of sickle cell disorders. 
Methods Mol Biol., Vol. 663, pp. 291-307. 
Mullis, K. (1990). The unusual origin of the polymerase chain reaction. Scientific American,
Vol. 262, No. 4, pp. 56–61. 
Nailis, H., Coenye, T., Van Nieuwerburgh, F., Deforce, D. & Nelis, H.J. (2006). Development 
and evaluation of different normalization strategies for gene expression studies in 
Candida albicans biofilms by real-time PCR. BMC Molecular Biology, Vol.  7, pp. 25. 
Nolan, T., Hands, R.E. & Bustin, S.A. (2006). Quantification of mRNA using real-time RT­
PCR. Nature Protocols, Vol. 1, No. 3, pp. 1559–1582. 
Nuwaysir, E.F., Huang, W., Albert, T.J., Singh, J., Nuwaysir, K., Pitas, A., Richmond, T., 
Gorski, T., Berg, J.P., Ballin, J., McCormick, M., Norton, J., Pollock, T., Sumwalt, T., 
Butcher, L., Porter, D., Molla, M., Hall, C., Blattner, F., Sussman, M.R., Wallace,
R.L., Cerrina, F. & Green, R.D. (2002). Gene expression analysis using 
oligonucleotide arrays produced by maskless photolithography. Genome Research,
Vol. 12, No. 11, pp. 1749–1755. 
Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT­
PCR. Nucleic Acids Research, Vol. 29, No. 9, e45. 
Pollack, J.R., Perou, C.M., Alizadeh, A.A., Eisen, M.B., Pergamenschikov, A., Williams, C.F.,
Jeffrey, S.S., Botstein, D. & Brown, P.O. (1999). Genome-wide analysis of DNA copy-
number changes using cDNA microarrays. Nature Genetics, Vol. 23, No. 1, pp. 41–46.
Purvey, S., Hanna, M., Shaib, W. & Saif, M.W. (2010). A case of Down syndrome who 
developed pancreatic cancer: a case report and review of literature. J Pancreas
online, Vol. 11, No. 3, pp. 285-7. 
Raelson, J.V., Little, R.D., Ruether, A., Fournier, H., Paquin, B., Van Eerdewegh, P., Bradley, W.E., 
Croteau, P., Nguyen-Huu, Q., Segal, J., Debrus, S., Allard, R., Rosenstiel, P., Franke, A.,
Jacobs, G., Nikolaus, S., Vidal, J.M., Szego, P., Laplante, N., Clark, H.F., Paulussen, R.J.,
Hooper, J.W., Keith, T.P., Belouchi, A. & Schreiber, S. (2007) Genome-wide association 
study for Crohn's disease in the Quebec Founder Population identifies multiple 
validated disease loci. PNAS USA, Vol. 104, No. 37, pp. 14747-52.  
Raheem, O., Olufemi, S.E., Bachinski, L.L., Vihola, A., Sirito, M., Holmlund-Hampf, J.,
Haapasalo, H., Li, Y.P., Udd, B.& Krahe, R. (2010). Mutant (CCTG)n expansion 
causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy 
type 2. Am J Pathol. Vol. 177, No. 6, pp. 3025-36. 
Rodgers, D.W., Gamblin, S.J., Harris, B.A., Ray, S., Culp, J.S., Hellmig, B., Woolf, D.J., 
Debouck, C. & Harrison, S.C. (1995). The structure of unliganded reverse 
www.intechopen.com
  
 
 
  
    
 
 
 
   
 
   
 
 
 
 
 
  
  
   
  
  
 
 
  
 
    
    
  
 
  
334 Gene Therapy - Developments and Future Perspectives 
transcriptase from the human immunodeficiency virus type 1. PNAS U.S.A., Vol. 
92, No. 4, pp. 1222–1226.  
Rodríguez-Caballero, A., Torres-Lagares, D., Rodríguez-Pérez, A., Serrera-Figallo, M.A., 
Hernández-Guisado, J.M. & Machuca-Portillo G. (2010) Cri du chat syndrome: a
critical review. Med Oral Patol Oral Cir Bucal. Vol. 15, No. 3, pp. 473-478.  
Schena, M., Shalon, D., Davis, R.W. & Brown, P.O. (1995). Quantitative monitoring of gene 
expression patterns with a complementary DNA microarray. Science, Vol.  270, No. 
5235, pp. 467–470. 
Shalon, D., Smith, S.J. & Brown, P.O. (1996). A DNA microarray system for analyzing 
complex DNA samples using two-color fluorescent probe hybridization. Genome
Research, Vol. 6, No. 7, pp. 639–645.  
Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. & Arnheim, N. (1985).
Enzymatic amplification of beta-globin genomic sequences and restriction site analysis
for diagnosis of sickle cell anemia. Science, Vol. 230, No. 4732, pp. 1350–1354.  
Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. & 
Erlich, H.A. (1988). Primer-directed enzymatic amplification of DNA with a
thermostable DNA polymerase. Science, Vol. 239, No. 4839, pp. 487–91. 
Saito, S., Ohno, K., & Sakuraba, H. (2011). Fabry-database.org: database of the clinical 
phenotypes, genotypes and mutant ǂ-galactosidase A structures in Fabry disease. J 
Human Genetics, [Epub ahead of print]. 
Spackman, E. & Suarez, D.L. (2008). Type A influenza virus detection and quantitation by
real-time RT-PCR. Methods Molecular Biology, Vol. 436, pp. 19–26.  
South, S.T., Hannes, F., Fisch, G.S., Vermeesch, J.R. & Zollino, M. (2008) Pathogenic 
significance of deletions distal to the currently described Wolf-Hirschhorn 
syndrome critical regions on 4p16.3. Am J Med Genet C Semin Med Genet. Vol. 15, 
No. 148C(4), pp. 270-4. 
Tang, T., François, N., Glatigny, A., Agier, N., Mucchielli, M.H., Aggerbeck, L. & Delacroix.
H. (2007). Expression ratio evaluation in two-colour microarray experiments is 
significantly improved by correcting image misalignment. Bioinformatics, Vol. 23,
No. 20, pp. 2686–2691.  
Temin, H. M. (1964a). Malignant transformation in cell culture. Health Lab. Sci., Vol. 1, pp. 79-83. 
Temin, H. M. (1964b). The participation of DNA in Rous sarcomavirus production. Virology, 
Vol. 23, pp. 486-494. 
Temin, H. M. (1964c). Homology between RNA from Rous sarcoma virus and DNA from
Rous sarcoma virus-infected cells. PNAS USA, Vol. 52, pp. 323-329. 
Valenti, R., Bianchi, S., Pescini, F., D'Eramo, C., Inzitari, D., Dotti, M.T. & Pantoni, L. (2011) 
First report of a pathogenic mutation on exon 24 of the NOTCH3 gene in a 
CADASIL family. J Neurology, [Epub ahead of print]. 
Warby, S.C., Visscher, H., Collins, J.A., Doty, C.N., Carter, C., Butland, S.L., Hayden, A.R.,
Kanazawa, I., Ross, C.J. & Hayden, M.R. (2011). HTT haplotypes contribute to
differences in Huntington disease prevalence between Europe and East Asia. 
European J Human Genetics [Epub ahead of print]. 
Wei, C., Li, J. & Bumgarner, R.E. (2004). Sample size for detecting differentially expressed 
genes in microarray experiments. BMC Genomics, Vol. 5, No. 1, pp. 87.
Wilson, M.G., Towner, J.W., Forsman, I. & Sims, E. (1979). Syndromes associated with deletion of
the long arm of chromosome 18[del(18q)]. Am. J. Med. Genet. Vol. 3, pp. 155-174 
Zipper, H., Brunner, H., Bernhagen, J. & Vitzthum, F. (2004). Investigations on DNA 
intercalation and surface binding by SYBR Green I, its structure determination and
methodological implications. Nucleic Acids Research, Vol. 32, No.12, e103. 
www.intechopen.com
Gene Therapy - Developments and Future Perspectives
Edited by Prof. Chunsheng Kang
ISBN 978-953-307-617-1
Hard cover, 356 pages
Publisher InTech
Published online 22, June, 2011
Published in print edition June, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The aim of this book is to cover key aspects of existing problems in the field of development and future
perspectives in gene therapy. Contributions consist of basic and translational research, as well as clinical
experiences, and they outline functional mechanisms, predictive approaches, patient-related studies and
upcoming challenges in this stimulating but also controversial field of gene therapy research. This source will
make our doctors become comfortable with the common problems of gene therapy and inspire others to delve
a bit more deeply into a topic of interest.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Safdar Ali and Sher Ali (2011). Differential Gene Expression and Its Possible Therapeutic Implications, Gene
Therapy - Developments and Future Perspectives, Prof. Chunsheng Kang (Ed.), ISBN: 978-953-307-617-1,
InTech, Available from: http://www.intechopen.com/books/gene-therapy-developments-and-future-
perspectives/differential-gene-expression-and-its-possible-therapeutic-implications
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
